Eli Lilly submits tirzepatide for approval in US and EU
Both the FDA and EMA have accepted Eli Lilly's marketing approval applications for its type 2 diabetes treatment, tirzepatide, the US-based pharmaceutical firm announces, also reporting that applications for seven additional markets have been submitted.
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen
Eli Lilly's tirzepatide, presumably the biggest contender for Novo Nordisk's newest generation of diabetes drugs, has taken a pivotal step on the pathway toward future market launches.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
.jpg)
WHO adds Novo Nordisk insulin to essential medicine lists
For subscribers
.jpg&w=384&q=75)
